Fanucci Marsha

SEC source: 0001193125-26-085871 · ownership.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,561

Underlying: Common Stock · 29,561 shares

Expires 2036-02-25

F1 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-24-070711 · ownership.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0000950170-24-070711 · ownership.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

SEC source: 0001209191-23-033723 · doc4.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0001209191-23-033723 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

SEC source: 0001735276-23-000061 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,454

Underlying: Common Stock · 3,454 shares

Expires 2033-05-18

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

SEC source: 0001735276-23-000016 · edgardoc.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 136 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date.

F2 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date.

SEC source: 0001735276-23-000016 · edgardoc.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-033658 · doc4.xml · derivative · entry 7

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,750 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0000899243-22-033658 · doc4.xml · derivative · entry 6

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,375 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0000899243-22-033658 · doc4.xml · derivative · entry 5

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,533 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0000899243-22-033658 · doc4.xml · derivative · entry 4

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,053 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0000899243-22-033658 · doc4.xml · derivative · entry 3

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,026 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

SEC source: 0000899243-22-033658 · doc4.xml · nonDerivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.

F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.

F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.

SEC source: 0000899243-22-033658 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

SEC source: 0001209191-22-050554 · doc4.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-09-15

F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

SEC source: 0001209191-22-050554 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

SEC source: 0001140361-22-023333 · form4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0000899243-22-021660 · doc4.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,750

Underlying: Common Stock · 6,750 shares

Expires 2032-06-07

F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-22-021660 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,782

F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.

SEC source: 0001209191-22-033708 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0001735276-22-000049 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,153

Underlying: Common Stock · 5,153 shares

Expires 2032-05-17

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

SEC source: 0001735276-22-000032 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Underlying: Common Stock · 136 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

SEC source: 0001735276-21-000065 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,032

Underlying: Common Stock · 4,032 shares

Expires 2031-07-14

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

SEC source: 0001140361-21-022578 · form4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0000899243-21-025091 · doc4.xml · derivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,375

Underlying: Common Stock · 8,375 shares

Expires 2031-06-16

F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-025091 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,282

F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.

SEC source: 0001209191-21-039576 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0001735276-20-000079 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0000899243-20-017609 · doc4.xml · nonDerivative · entry 5

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 9,847 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of 0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock.

SEC source: 0000899243-20-017609 · doc4.xml · nonDerivative · entry 4

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 9,847 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of 0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock.

SEC source: 0000899243-20-017609 · doc4.xml · nonDerivative · entry 3

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 9,847 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of 0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock.

SEC source: 0000899243-20-017609 · doc4.xml · nonDerivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 9,847 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of 0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock.

SEC source: 0000899243-20-017609 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,532

F1 · price: Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 33,781 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 9,847 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (iii) 10,240 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, and (iv) 14,026 shares of Enterprise 5 Junior Stock at a conversion rate of 0.6727 shares of common stock per one share of Enterprise 5 Junior Stock, resulting in her acquisition of 52,532 shares of common stock.

SEC source: 0000899243-20-017439 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,533 shares

Expires 2030-06-17

F1 · derivative.exercise_date: The shares subject to this stock option shall vest upon the earlier of June 18, 2021 or the date of the next annual shareholder meeting of the Issuer following the date of grant.

SEC source: 0001209191-20-037580 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001209191-20-035966 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 9

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2023-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 8

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2021-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 7

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2022-06-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 6

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2020-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

F2 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.

SEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 5

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 4

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 3

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 2

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018.

SEC source: 0001735276-19-000060 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2029-06-30

SEC source: 0001209191-19-036359 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

SEC source: 0001209191-19-034373 · doc4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-01

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001209191-19-023411 · doc4.xml · nonDerivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,663

F1 · price: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.